Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by buylow4on Nov 17, 2009 9:06pm
680 Views
Post# 16497641

RE: re - projected US sales next year?

RE: re - projected US sales next year?Gadshill,  this is part of a previous post of mine dating back to July:


Now, projected sales in the US are expected to be about $300MM.  This won't happen overnight, it will take some time.  Also, any shareholder would also expect this company to continue to invest in R&D so that it can eventually bring more to the table.....this will also take time and eat up resources.

So....let's look down the road a couple of years and go with the assumption that the company is generating $500MM in sales and $30MM in earnings (6% of sales).  By the time all warrants are exercised, the company will have close to 400MM shares.  So.....basically we're looking at earnings per share of about
.075/share.

I've been using a multiple of 15 because it appears to be the norm for many of the established and well run companies in this industry.

Therefore, the SP of this company, in the future can very well get to $1.13.  Assuming all factors are in play as stated above.

Now......as you know, we are nowhere near that stage right now.  If FDA approval is granted, are you willing to pay over $1.00 per share......I would hope not.   You would wait and see whether the distribution is effective, whether the revenues can be sustained, and whether management can grow this company further.

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse